Gallagher Kathleen P.
SEC CIK 2048409 · EDGAR
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| RNA | Atrium Therapeutics, Inc. | See Remarks, Dir | 119.7K | — | — | 2 | 2026-04-20 | 2026-09-18 |
Most active insiders at RNA, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Younis Husam | CSO | — | — |
| 2 | Hoyos Rocio Martin | Chief Strategy Off | — | — |
| 3 | Winslow Brendan R. | CFO | — | — |
| 4 | Kenney Stephanie | See Remarks | — | — |
| 5 | Gallagher Kathleen P. | See Remarks, Dir | — | — |
| 6 | Flanagan W. Michael | Dir | — | — |
| 7 | Hughes Steven George | Chief Medical Off | — | — |
| 8 | Boyce Sarah | Dir | — | — |
Transactions 2
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-22 16:17 | 2026-09-18 | RNA | Atrium Therapeutics, Inc. | Gallagher Kathleen P. | See Remarks, Dir | F - Tax | $8.95 | -11.6K | 119.7K | -9% | -$104.1K | |
| D | 2026-04-22 17:43 | 2026-04-20 | RNA | Atrium Therapeutics, Inc. | Gallagher Kathleen P. | See Remarks, Dir | A - Grant | $0.00 | +102.5K | 131.4K | +355% | $0 |
Purchase Sale Sale after option exercise All abbreviations